Literature DB >> 6654575

Plasma phentermine levels, weight loss and side-effects.

A Douglas, J G Douglas, C E Robertson, J F Munro.   

Abstract

Fifty women with refractory obesity received phentermine resinate. Seven were withdrawn because of side-effects: three developed severe headaches, one each hypertension, depressive symptoms, breathlessness and palpitations with irritability. The mean weight loss in the 34 who completed the 20-week study was 6.4 kg. Nine lost 10 kg or more. Sustained appetite suppression was related to weight loss. Plasma phentermine concentrations did not correlate with the severity of the obesity problem, the degree of subjective anorexia or with weight loss. Poor initial response to standard dosage of phentermine is unlikely to improve with higher dosage. The individual's response to phentermine is unpredictable and appears to relate to factors other than the plasma drug concentration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6654575

Source DB:  PubMed          Journal:  Int J Obes


  7 in total

Review 1.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Appetite suppressants. A review.

Authors:  T Silverstone
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

3.  RE: Pulmonary hypertension associated with use of phentermine?

Authors:  Ed J Hendricks; Richard B Rothman
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

Review 4.  Induction of thermogenic adipocytes: molecular targets and thermogenic small molecules.

Authors:  No-Joon Song; Seo-Hyuk Chang; Dean Y Li; Claudio J Villanueva; Kye Won Park
Journal:  Exp Mol Med       Date:  2017-07-07       Impact factor: 8.718

Review 5.  Off-label drugs for weight management.

Authors:  Ed J Hendricks
Journal:  Diabetes Metab Syndr Obes       Date:  2017-06-10       Impact factor: 3.168

6.  Phentermine, sibutramine and affective disorders.

Authors:  Hoyoung An; Hyunjoo Sohn; Seockhoon Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-04-24       Impact factor: 2.582

Review 7.  Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.

Authors:  Arianne N Sweeting; Eddy Tabet; Ian D Caterson; Tania P Markovic
Journal:  Diabetes Metab Syndr Obes       Date:  2014-02-12       Impact factor: 3.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.